|
Q4 FY2025
As of Dec 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q4 FY2020
As of Dec 31, 2020
|
Q4 FY2019
As of Dec 31, 2019
|
Q4 FY2018
As of Dec 31, 2018
|
Q4 FY2017
As of Dec 31, 2017
|
Q4 FY2016
As of Dec 31, 2016
|
Q4 FY2011
As of Dec 31, 2011
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Current assets | |||||||||||
| Cash and cash equivalents | |||||||||||
| Restricted cash | |||||||||||
| Income taxes receivable | |||||||||||
| Inventory (note 15) | |||||||||||
| Derivative instruments (notes 16 and 17) | |||||||||||
| Regulatory assets (note 7) | |||||||||||
| Other current assets | |||||||||||
| Receivables and other current assets (note 19) | |||||||||||
| Assets held for sale (note 4) | |||||||||||
| Total current assets | |||||||||||
| Property, plant and equipment ("PP&E"), net of accumulated depreciation and amortization of $10,845 and $10,442, respectively (note 21) | |||||||||||
| Other assets | |||||||||||
| Deferred income taxes (note 11) | |||||||||||
| Derivative instruments (notes 16 and 17) | |||||||||||
| Regulatory assets (note 7) | |||||||||||
| Net investment in direct finance and sales type leases (note 20) | |||||||||||
| Investments subject to significant influence (note 8) | |||||||||||
| Goodwill (note 23) | |||||||||||
| Other long-term assets (note 33) | |||||||||||
| Assets held for sale (note 4) | |||||||||||
| Total other assets | |||||||||||
| Total assets | |||||||||||
| Liabilities and Equity | |||||||||||
| Current liabilities | |||||||||||
| Short-term debt (note 24) | |||||||||||
| Current portion of long-term debt (note 26) | |||||||||||
| Accounts payable | |||||||||||
| Income taxes payable | |||||||||||
| Derivative instruments (notes 16 and 17) | |||||||||||
| Regulatory liabilities (note 7) | |||||||||||
| Pension and post-retirement liabilities | |||||||||||
| Other current liabilities (note 25) | |||||||||||
| Liabilities associated with assets held for sale (note 4) | |||||||||||
| Total current liabilities | |||||||||||
| Long-term liabilities | |||||||||||
| Long-term debt (note 26) | |||||||||||
| Deferred income taxes (note 11) | |||||||||||
| Derivative instruments (notes 16 and 17) | |||||||||||
| Regulatory liabilities (note 7) | |||||||||||
| Pension and post-retirement liabilities (note 22) | |||||||||||
| Other long-term liabilities (notes 8 and 27) | |||||||||||
| Liabilities associated with assets held for sale (note 4) | |||||||||||
| Total long-term liabilities | |||||||||||
| Equity | |||||||||||
| Common stock (note 12) | |||||||||||
| Cumulative preferred stock (note 29) | |||||||||||
| Contributed surplus | |||||||||||
| Accumulated other comprehensive income ("AOCI") (note 14) | |||||||||||
| Retained earnings | |||||||||||
| Total Emera Incorporated equity | |||||||||||
| NCI (note 30) | |||||||||||
| Total equity | |||||||||||
| Total liabilities and equity | |||||||||||
Loading...